September 18, 2026 · Blood · DOI: 10.1182/blood.2026033895

Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia

Listen to this summary

The authors aimed to evaluate the impact of adding a tyrosine kinase inhibitor (TKI) to intensive chemotherapy (IC) on the outcomes of patients with de novo BCR::ABL1+ acute myeloid leukemia (AML). Their analysis of 212 patients revealed that the combination of IC and TKI significantly improved complete remission rates and overall survival compared to IC alone, suggesting that this approach should be considered the standard of care and prompting a reevaluation of the classification of this condition as adverse-risk.

Sarah Bertoli, Niklas Landberg, Emilie Bérard, Camille Gondran, Laetitia Largeaud, Véronique Mansat-De Mas, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Sylvain Garciaz, Ludovic Gabellier, Gabrielle Roth Guepin, Corentin Orvain, Pierre Peterlin, Rudy Birsen, Magda Alexis, Martin Carré, Emmanuelle Tavernier, Marion Boissard Simonet, Chantal Himberlin, Marc Maynadié, Kamel Laribi, Cécile Moluçon Chabrot, Amine Belhabri, Samy Chraibi, Quentin Cabrera, Delphine Lebon, Emmanuel Raffoux, Thomas Cluzeau, Jean-Baptiste Micol, Mathieu Leclerc, Céline Berthon, Hervé Dombret, Gunnar Juliusson, Anna Robelius, Soren Lehmann, Martin Jädersten, Lovisa Vennström, Pau Montesinos, Carmen Botella, Juan Miguel Bergua Burgues, Raimundo Garcia, Josefina Serrano, Maria Luz Amigo, Patricia García Ramirez, Claudia Lucía Sossa-Melo, Juan Manuel Alonso-Domínguez, Hartmut Döhner, Konstanze Döhner, Daniela Späth, Michael Wm Kühn, Claudia Lengerke, Hans-Jörg Tischler, Christoph Röllig, Leo Ruhnke, Christian Thiede, Andreas Burchert, Hubert Serve, Carsten Müller-Tidow, Claudia D Baldus, Jurjen Versluis, Peter Jm Valk, Daniel Tuyet Kristensen, Anne Stidsholt Roug, Jiri Mayer, Mika Kontro, Pia Ettala, Vladimir Lj Lazarevic, Christian Récher

This is one of 33,000+ journals available on OSLR. Try it free for 14 days.

Free 14-day trial. 33,000+ journals. Cancel anytime.

14-day free trial. No commitment.

"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."

Dr. Jennifer Thompson

Dr. Jennifer Thompson

Portland, OR

Stay current without falling behind

33,000+ journals. 3-minute audio summaries. Free for 14 days.

Download on the App StoreGet it on Google Play